VALN

Valneva SE ADR

Mar 18 • 04:00PM ET

11.19

0.00 0.00 %

Healthcare • Biotechnology • France • NASD

Mar 18, 5:05 PMValneva reports 2025 revenue above 170 million, swings to €82.1 million operating loss, guides lower 2026 third‑party product sales

Peers: PFE JNJ MRNA AZN-D GSK NVAX BNTX SRPT VXRT INBX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	5.34%	Shs Outstand	85.87M	Perf Week	-0.18%
Market Cap	962.79M	Forward P/E	13.74	EPS next Y	0.81	Insider Trans	0.00%	Shs Float	81.45M	Perf Month	3.90%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.16	Inst Own	0.70%	Short Float	0.17%	Perf Quarter	30.12%
Income	-114.14M	P/S	4.88	EPS this Y	36.52%	Inst Trans	-1.19%	Short Ratio	7.25	Perf Half Y	26.01%
Sales	197.44M	P/B	5.43	EPS next Y	181.92%	ROA	-20.69%	Short Interest	0.14M	Perf YTD	26.87%
Book/sh	2.06	P/C	5.71	EPS next 5Y	-	ROE	-54.41%	52W High	12.25 -8.65%	Perf Year	65.04%
Cash/sh	1.96	P/FCF	-	EPS past 3/5Y	53.24% -33.67%	ROIC	-34.11%	52W Low	5.43 106.12%	Perf 3Y	5.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-23.61% 5.37%	Gross Margin	54.18%	Volatility	4.41% 3.94%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.19	EPS Y/Y TTM	-1442.18%	Oper. Margin	-50.39%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.36	Sales Y/Y TTM	14.85%	Profit Margin	-57.81%	RSI (14)	56.03	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	1.78	EPS Q/Q	-382.57%	SMA20	2.19%	Beta	1.76	Target Price	16.42
Payout	-	Debt/Eq	1.30	Sales Q/Q	-31.73%	SMA50	9.13%	Rel Volume	0.00	Prev Close	11.19
Employees	713	LT Debt/Eq	0.89	Earnings	Mar 18 BMO	SMA200	24.94%	Avg Volume	19.11K	Price	11.19
IPO	May 06, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-89.14% 4.67%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Resumed	H.C. Wainwright	Buy	$18
Aug-03-22	Initiated	H.C. Wainwright	Buy	$34

Mar-18-26 05:00PM	Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
08:00AM	Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program (PR Newswire)
Feb-19-26 11:00AM	Valnevas Lyme disease vaccine offers beacon of hope amid 2025 sales dip (Pharmaceutical Technology)
Jan-20-26 03:58PM	Valneva Steps Back From US Approval Bid For Chikungunya Vaccine (Benzinga)
06:47AM	Valneva to withdraw Chikungunya vaccine from US amid safety woes (BioPharma Dive)
01:15PM	Loading…
Nov-27-25 01:15PM	Valneva trims R&D footprint by shutting French facility (Pharmaceutical Technology)
Nov-26-25 06:37AM	Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study (The Wall Street Journal) +9.15%
Nov-20-25 06:17AM	Valneva misses revenue estimates, reaffirms guidance; stock jumps (Investing.com)
Sep-09-25 06:48PM	A Lyme Disease Vaccines Final Test Results Could Appear By Yearend. (Barrons.com)
Aug-18-25 01:00AM	Valnevas Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older (GlobeNewswire) +5.29%
Aug-12-25 01:00AM	Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +10.59%
Aug-11-25 09:25AM	Valneva SE (VALN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -6.70%
Aug-07-25 01:18AM	Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information (GlobeNewswire)
Aug-05-25 12:00PM	VALNEVA Declaration of shares and voting rights: July 31, 2025 (GlobeNewswire)
Jul-24-25 08:44AM	Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock? (Zacks)
11:35AM	Loading…
Jul-11-25 11:35AM	Valneva Announces Lifting of European Medicines Agencys Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly (GlobeNewswire)
Jul-03-25 12:00PM	VALNEVA Declaration of shares and voting rights: June 30, 2025 (GlobeNewswire)
Jun-26-25 01:00AM	Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus (GlobeNewswire)
Jun-25-25 11:45AM	Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance (GlobeNewswire)
Jun-10-25 09:30AM	UK restricts use of Valneva chikungunya vaccine for safety review (TipRanks)
Jun-05-25 11:45AM	Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® (GlobeNewswire)
01:30AM	[Valneva SE] Declaration of shares and voting rights - May 2025 (GlobeNewswire)
Jun-04-25 01:00AM	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update (GlobeNewswire)
May-26-25 11:30AM	Valneva to Participate at U.S. and European Investor Conferences in June (GlobeNewswire)
May-12-25 01:00AM	Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States (GlobeNewswire)
May-08-25 12:30AM	Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance (Seeking Alpha)
May-07-25 12:28PM	Valneva dips as EU suspends use of chikungunya shot in older adults (Seeking Alpha)
12:00PM	VALNEVA Declaration of shares and voting rights: April 30, 2025 (GlobeNewswire)
11:45AM	Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly (GlobeNewswire)
01:00AM	Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
01:10PM	Loading…
Apr-26-25 01:10PM	Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities (GlobeNewswire)
Apr-18-25 04:00AM	Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ Among U.S. Travelers (GlobeNewswire)
Apr-16-25 11:45AM	Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ (GlobeNewswire) -6.88%
04:52AM	Valneva SE: Initiating Hold Rating Based On Potentially Limited Upside (Seeking Alpha)
Apr-14-25 11:45AM	Valneva Receives First Marketing Authorization for IXCHIQ in a Chikungunya Endemic Country (GlobeNewswire) +12.08%
Apr-10-25 07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks) -6.79%
Apr-09-25 01:00AM	Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 (GlobeNewswire) +12.09%
Apr-03-25 11:45AM	Valneva SE Shareholding Declaration - March 2025 (GlobeNewswire)
Apr-01-25 12:51PM	Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025? (Insider Monkey)
11:45AM	Valneva's Chikungunya Vaccine IXCHIQ Now Authorized in EU for Adolescents Aged 12 and Above (GlobeNewswire)
Mar-31-25 01:00AM	Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ , to UK MHRA (GlobeNewswire) -7.58%
Mar-26-25 01:00PM	Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program (GlobeNewswire)
Mar-25-25 02:00AM	Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F (GlobeNewswire)
Mar-24-25 02:00AM	Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ against Chikungunya Outbreak in La R union (GlobeNewswire)
Mar-20-25 08:02PM	Valneva outlines 170M-180M sales target for 2025 with focus on IXCHIQ and Lyme vaccine developments (SeekingAlpha) +7.73%
08:00PM	Valneva SE (VALN) Q4 2024 Earnings Call Transcript (SeekingAlpha)
02:00AM	Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook (GlobeNewswire)
Mar-05-25 12:00PM	VALNEVA Declaration of shares and voting rights: February 28, 2025 (GlobeNewswire)
Mar-03-25 01:00AM	Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences (GlobeNewswire)
Feb-28-25 11:45AM	Valneva Receives EMAs Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® (GlobeNewswire) -5.20%
Feb-18-25 01:00AM	Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook (GlobeNewswire) +9.90%
Feb-06-25 12:00PM	Shareholding declaration Valneva SE - January 2025 (GlobeNewswire)
Feb-05-25 01:00AM	Valneva Receives Marketing Authorization in the UK for the Worlds First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire) +18.89%
Jan-30-25 11:45AM	Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million (GlobeNewswire)
Jan-22-25 11:45AM	Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision (GlobeNewswire)
Jan-20-25 11:45AM	Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine (GlobeNewswire)
Jan-06-25 11:45AM	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-25 12:00PM	VALNEVA Declaration of shares and voting rights: December 31, 2024 (GlobeNewswire)
Dec-20-24 06:31AM	Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia (TipRanks) -8.28%
Dec-19-24 02:00AM	Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India (GlobeNewswire) +17.20%
Dec-05-24 01:30AM	VALNEVA - Declaration of shares and voting rights: November 30, 2024 (GlobeNewswire)
Dec-04-24 01:00AM	Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal (GlobeNewswire)
Dec-03-24 01:00AM	Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ (GlobeNewswire)
Nov-26-24 11:45AM	Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ , to the U.S. FDA (GlobeNewswire) -6.91%
Nov-15-24 05:19AM	European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department (The Wall Street Journal) -5.86%
Nov-13-24 11:45AM	Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 (GlobeNewswire)
Nov-12-24 01:00AM	Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences (GlobeNewswire) -6.63%
Nov-07-24 01:00AM	Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-06-24 02:30AM	VALNEVA - Declaration of shares and voting rights: October 31, 2024 (GlobeNewswire)
Oct-21-24 11:45AM	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
Oct-16-24 11:45AM	Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V (GlobeNewswire)
Oct-10-24 01:00AM	Valneva Hosts Investor Day in New York City (GlobeNewswire)
Oct-04-24 01:30AM	Valneva SE - Declaration of shares and voting rights - September 30, 2024 (GlobeNewswire)
Oct-03-24 01:00AM	Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET (GlobeNewswire)
Sep-18-24 01:00AM	Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ , to EMA and Health Canada (GlobeNewswire)
Sep-13-24 02:30AM	Valneva Announces the Success of its Private Placement Raising approximately 60 Million (GlobeNewswire) -8.52%
Sep-12-24 04:05PM	Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros (GlobeNewswire)
Sep-04-24 12:00PM	VALNEVA - Declaration of shares and voting rights: August 31, 2024 (GlobeNewswire)
Sep-03-24 01:00AM	Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
Aug-13-24 01:00AM	Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +7.35%
Aug-06-24 02:30AM	VALNEVA - Declaration of shares and voting rights: July 31, 2024 (GlobeNewswire)
Aug-01-24 01:00AM	Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate (GlobeNewswire)
Jul-29-24 03:04PM	3 Promising Biotech Stocks You Can Pick Up for Less Than $10 (InvestorPlace)
Jul-22-24 01:00AM	CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine (GlobeNewswire)
Jul-17-24 04:00PM	Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion (GlobeNewswire)
Jul-08-24 12:45PM	Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine (Zacks)
Jul-04-24 12:00PM	Declaration of shares and voting rights - Valneva SE - June 30, 2024 (GlobeNewswire)
Jul-01-24 01:00AM	Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
Jun-26-24 11:45AM	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board (GlobeNewswire)
Jun-24-24 11:27AM	Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval (Zacks) +8.90%
01:00AM	Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
Jun-05-24 01:00AM	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update (GlobeNewswire)
Jun-04-24 12:00PM	VALNEVA - Declaration of shares and voting rights: May 31, 2024 (GlobeNewswire)
11:35AM	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
Jun-03-24 11:35AM	Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases (GlobeNewswire)
May-31-24 11:35AM	Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine (GlobeNewswire)
May-21-24 01:00AM	Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (GlobeNewswire) -7.24%
May-13-24 08:53AM	VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
01:00AM	Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine (GlobeNewswire)
May-07-24 01:00AM	Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VALN

Valneva SE ADR

Upgrade your FINVIZ experience